ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study to Evaluate Botulinum Neurotoxin Serotype E (EB-001) in Reducing Musculoskeletal Pain in Abdominoplasty

Phase 2

Terminated

Conditions: Abdominoplasty

Interventions: Drug: Placebo
Biological: Botulinum Neurotoxin Serotype E

First Posted Date: 2018-02-12

Last Posted Date: 2019-08-05

Lead Sponsor: Allergan

Target Recruit Count: 23

Registration Number: NCT03429556

Locations: 🇺🇸
Huntington Ambulatory Surgery Center, Pasadena, California, United States
🇺🇸
Lotus Clinical Research, LLC, Pasadena, California, United States

Histological and Microbiological Evaluation of Late Occurring Nodules With Hyaluronic Acid Dermal Fillers

Completed

Conditions: Dermal Nodule

Interventions: Other: No Intervention

First Posted Date: 2018-02-08

Last Posted Date: 2021-08-06

Lead Sponsor: Allergan

Target Recruit Count: 17

Registration Number: NCT03425721

Locations: 🇺🇸
Assure Surgical, P.C., New York, New York, United States
🇺🇸
Skin Care and Laser Physicians (SCLP) of Beverly Hills, West Hollywood, California, United States

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

Phase 3

Terminated

Conditions: Gastroparesis
Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Relamorelin

First Posted Date: 2018-02-08

Last Posted Date: 2021-08-06

Lead Sponsor: Allergan

Target Recruit Count: 311

Registration Number: NCT03426345

Locations: 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
The Ohio State University, Wexner Medical Center, Columbus, Ohio, United States

and more 230 locations

Sequential Treatment With BELKYRA® Then Juvéderm® VOLUMA™ With Lidocaine for Overall Improvement in Jawline Contour

Phase 4

Completed

Conditions: Contour

Interventions: Drug: BELKYRA®
Device: Juvéderm® VOLUMA™ with Lidocaine

First Posted Date: 2018-02-07

Last Posted Date: 2020-12-31

Lead Sponsor: Allergan

Target Recruit Count: 58

Registration Number: NCT03425253

Locations: 🇦🇺
Living Art, East Melbourne, Victoria, Australia
🇦🇺
Darlinghurst Dermatology, Darlinghurst, New South Wales, Australia
🇦🇺
Dermatology Institute of Victoria, South Yarra, Victoria, Australia

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

Phase 3

Terminated

Conditions: Gastroparesis
Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Relamorelin

First Posted Date: 2018-02-05

Last Posted Date: 2021-12-22

Lead Sponsor: Allergan

Target Recruit Count: 467

Registration Number: NCT03420781

Locations: 🇺🇸
Gastroenterology Associates of Fairfield County, P.C., Bridgeport, Connecticut, United States
🇺🇸
Applied Research Center of Arkansas, Little Rock, Arkansas, United States
🇺🇸
Kindred Medical Institute for Clinical Trials, LLC, Corona, California, United States

and more 329 locations

A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing

Phase 3

Completed

Conditions: Infraorbital Hollowing

Interventions: Device: JUVÉDERM VOLBELLA® XC injectable gel

First Posted Date: 2018-02-01

Last Posted Date: 2021-11-15

Lead Sponsor: Allergan

Target Recruit Count: 163

Registration Number: NCT03418545

Locations: 🇺🇸
Steve Yoelin MD Medical Associate, Inc., Newport Beach, California, United States
🇺🇸
Cosmetic Laser Dermatology, San Diego, California, United States
🇺🇸
Facesplus, Inc., San Diego, California, United States

and more 12 locations

Physiopathologic Aspects and Quality of Life in Participants With Eye Dark Circles

Completed

Conditions: Periorbital Hyperpigmentation

Interventions: Device: Skin imaging
Other: Facial cleanser

First Posted Date: 2018-01-17

Last Posted Date: 2019-01-23

Lead Sponsor: Allergan

Target Recruit Count: 44

Registration Number: NCT03400202

Locations: 🇺🇸
SkinMedica Clinical Research and Innovation Center, Irvine, California, United States

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

Phase 3

Terminated

Conditions: Gastroparesis
Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Relamorelin

First Posted Date: 2017-12-26

Last Posted Date: 2021-11-23

Lead Sponsor: Allergan

Target Recruit Count: 450

Registration Number: NCT03383146

Locations: 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸
Endocrinology Research Associates, Inc., Columbus, Ohio, United States
🇺🇸
Texas Clinical Research Institute, LLC, Arlington, Texas, United States

and more 331 locations

Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Phase 1

Completed

Conditions: Hepatic Impairment

Interventions: Drug: Cenicriviroc

First Posted Date: 2017-12-19

Last Posted Date: 2018-01-11

Lead Sponsor: Allergan

Target Recruit Count: 16

Registration Number: NCT03376841

Locations: 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
Clinical Pharmacology of Miami, Miami, Florida, United States

Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma

Phase 3

Completed

Conditions: Angle-Closure
Glaucoma

Interventions: Device: XEN45

First Posted Date: 2017-12-05

Last Posted Date: 2023-05-17

Lead Sponsor: Allergan

Target Recruit Count: 65

Registration Number: NCT03362931

Locations: 🇸🇬
Tan Tock Seng Hospital /ID# 233014, Singapore, Singapore
🇨🇳
Buddhist Tzu Chi General Hospital /ID# 232664, Hualien, Taiwan
🇸🇬
Nuh Medical Centre /ID# 232905, Singapore, Singapore

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy